GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Cantel Medical Corp (NYSE:CMD) » Definitions » EBIT

Cantel Medical (Cantel Medical) EBIT : $131 Mil (TTM As of Apr. 2021)


View and export this data going back to 1992. Start your Free Trial

What is Cantel Medical EBIT?

Cantel Medical's earnings before interest and taxes (EBIT) for the three months ended in Apr. 2021 was $46 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Apr. 2021 was $131 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Cantel Medical's annualized ROC % for the quarter that ended in Apr. 2021 was 7.41%. Cantel Medical's annualized ROC (Joel Greenblatt) % for the quarter that ended in Apr. 2021 was 41.97%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Cantel Medical's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Apr. 2021 was 3.18%.


Cantel Medical EBIT Historical Data

The historical data trend for Cantel Medical's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cantel Medical EBIT Chart

Cantel Medical Annual Data
Trend Jul11 Jul12 Jul13 Jul14 Jul15 Jul16 Jul17 Jul18 Jul19 Jul20
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only 97.25 110.54 122.80 84.82 48.31

Cantel Medical Quarterly Data
Jul16 Oct16 Jan17 Apr17 Jul17 Oct17 Jan18 Apr18 Jul18 Oct18 Jan19 Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 22.44 3.84 50.35 31.63 45.52

Competitive Comparison of Cantel Medical's EBIT

For the Medical Instruments & Supplies subindustry, Cantel Medical's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cantel Medical's EV-to-EBIT Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Cantel Medical's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Cantel Medical's EV-to-EBIT falls into.



Cantel Medical EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Apr. 2021 adds up the quarterly data reported by the company within the most recent 12 months, which was $131 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cantel Medical  (NYSE:CMD) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Cantel Medical's annualized ROC % for the quarter that ended in Apr. 2021 is calculated as:

ROC % (Q: Apr. 2021 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Jan. 2021 ) + Invested Capital (Q: Apr. 2021 ))/ count )
=182.096 * ( 1 - 31.16% )/( (1690.136 + 1691.335)/ 2 )
=125.3548864/1690.7355
=7.41 %

where

Invested Capital(Q: Jan. 2021 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=2050.31 - 117.113 - ( 243.061 - max(0, 234.547 - 638.04+243.061))
=1690.136

Invested Capital(Q: Apr. 2021 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=2031.278 - 121.415 - ( 218.528 - max(0, 242.954 - 625.997+218.528))
=1691.335

Note: The Operating Income data used here is four times the quarterly (Apr. 2021) data.

2. Joel Greenblatt's definition of Return on Capital:

Cantel Medical's annualized ROC (Joel Greenblatt) % for the quarter that ended in Apr. 2021 is calculated as:

ROC (Joel Greenblatt) %(Q: Apr. 2021 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Jan. 2021  Q: Apr. 2021
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=182.096/( ( (276.158 + max(149.941, 0)) + (276.568 + max(165.046, 0)) )/ 2 )
=182.096/( ( 426.099 + 441.614 )/ 2 )
=182.096/433.8565
=41.97 %

where Working Capital is:

Working Capital(Q: Jan. 2021 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(159.372 + 170.075 + 22.388) - (117.113 + 29.908 + 54.873)
=149.941

Working Capital(Q: Apr. 2021 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(164.929 + 179.078 + 23.911) - (121.415 + 30.903 + 50.554)
=165.046

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Apr. 2021) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Cantel Medical's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Apr. 2021 )
=131.348/4125.665
=3.18 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cantel Medical EBIT Related Terms

Thank you for viewing the detailed overview of Cantel Medical's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Cantel Medical (Cantel Medical) Business Description

Traded in Other Exchanges
N/A
Address
150 Clove Road, 9th Floor, Little Falls, NJ, USA, 07424
Cantel Medical is a New Jersey-based manufacturer of hospital supplies for infection prevention, which include products used in endoscope disinfection, water purification systems for use in dialysis treatment, and dental supplies. The firm reports in four segments: medical (46% of fiscal 2020 sales), dental (32%), life sciences (19%), and dialysis (3%). Geographic exposure is primarily in the U.S., which accounts for about 75% of revenue, with international markets making up the remaining 25%.
Executives
Ann E Berman director 255 STATE STREET, BOSTON MA 02109
Jeffrey Z Mann officer: SVP, General Counsel 150 CLOVE ROAD, 9TH FLOOR, LITTLE FALLS NJ 07424
George L Fotiades director, officer: Chief Executive Officer 281 SUMMIT AVENUE, SUMMIT NJ 07901
Charles M Diker director, 10 percent owner, officer: Chairman ONE NEW YORK PLAZA, NEW YORK NY 10004
Shaun M. Blakeman officer: SVP - CFO C/O CANTEL MEDICAL CORP., 150 CLOVE ROAD, LITTLE FALLS NJ 07424
Jean Casner officer: SVP and CHRO 150 CLOVE ROAD, LITTLE FALLS NJ 07424
Brian Capone officer: SVP and Princ. Accounting Ofr 150 CLOVE ROAD, 9TH FLOOR, LITTLE FALLS NJ 07424
Peter G Clifford officer: President and COO 40 TOURNAMENT DRIVE SOUTH, HAWTHORN WOODS IL 60047
Seth M Yellin officer: Executive Vice President 150 CLOVE ROAD 9TH FLOOR LITTLE FALLS NJ 07424
Laura L Forese director 849 STONEWALL COURT FRANKLIN LAKES NJ 07417
Peter Pronovost director JHU-QSRG 1909 THAMES ST. - 2ND FLOOR BALTIMORE MD 21231
Anthony B Evnin director C/O VENROCK ASSOCIATES, 7 BRYANT PARK, 23RD FLOOR, NEW YORK NY 10018
Ronnie Myers director TOURO COLLEGE OF DENTAL MEDICINE 40 SUNSHINE COTTAGE ROAD VALHALLA NY 10595
Alan R Batkin director 399 PARK AVENUE, 10TH FLOOR, NEW YORK NY 10022
Karen Prange director 1108 S RIO VISTA BLVD, FORT LAUDERDALE FL 33316

Cantel Medical (Cantel Medical) Headlines

From GuruFocus

Cantel Hires Michael Drexel to SVP and Chief Technology Officer

By PRNewswire PRNewswire 10-01-2020

Cantel Pre-Announces Estimated Revenue for the 1st Quarter

By PRNewswire PRNewswire 10-22-2020